Morphea Clinical Trials
Here are the 6 most popular medical studies for morphea
Enzyme
Hyaluronidase + CO2 Laser for Small Mouth
This trial explores combining two treatments to improve mouth mobility, hygiene, self-esteem, and quality of life for people with scleroderma-induced microstomia. Laser-assisted drug delivery used to reduce pain of injections. 3 laser sessions at 4-8 week intervals, followed by 3mo follow-up.
Phototherapy
UVA-1 Phototherapy for Scleroderma
This trial will use a single-blind, prospective, randomized (dominant/non-dominant hand) comparator design to assess the effect of high dose (80-120 J/cm2) UVA1 therapy on hand function in scleroderma in a paired t-test design. This study will be placebo-controlled (with a UV-blocking gloved hand), cross-over, randomized clinical trial.
Monoclonal Antibodies
Belimumab + Rituximab for Systemic Sclerosis
This trial will test whether a combination of Belimumab & Rituximab, given on top of standard Mycophenolate Mofetil therapy, can improve fibrosis in early diffuse cutaneous systemic sclerosis (dcSSc) patients.
Popular filter options for morphea trials
SSc Clinical Trials
View 28 SSc medical studies.
Monoclonal Antibodies
Brentuximab Vedotin for Systemic Sclerosis
This trial aims to test the safety and effectiveness of Brentuximab vedotin in patients with a certain type of skin disease called diffuse cutaneous systemic sclerosis who have not responded well to previous treatment
Behavioural Intervention
Online Fatigue Management for Scleroderma
This trial is testing whether an online fatigue management program can help reduce fatigue, pain, and increase confidence in managing fatigue and daily activities. It involves completing surveys before and after the intervention, and attending and participating in 1.5 hour weekly videoconference meetings for 6 weeks.
Skin involvement for Systemic Sclerosis
Systemic Sclerosis (SSc) is an autoimmune connective tissue disease characterized by autoantibodies, fibrosis and microvascular injury and endothelial cell activation that results in vascular damage. Vascular injury induces both innate and acquired immune responses resulting in fibroblast activation and organ fibrosis. SSc may target multiple organs, including: skin, lungs, heart, vascularization, kidneys, the gastrointestinal tract and musculoskeletal structures. Mortality among scleroderma patients is significant, with a 3.5 standardized mortality ratio (SMR) in studies of prevalent cases. This mortality may be increased in the early years of the disease, reaching a SMR of 4 in a multinational inception cohort. In general, treatment strategies target involved organs as early as possible to avoid damage. Many treatment options are available for each manifestation, but evidence with respect to the order of treatment is scarce. Financial costs, the lack of proper outcome measures, difficulty to recruit patients as a rare disease, all prevent the development of new big clinical trials, oppositely to other common diseases such as stroke or cancer. The heterogeneous features of SSc may make trials challenging. The current guidelines available are the British guidelines (2017) , and the updated European League Against Rheumatism (EULAR) guidelines, published in 2017. Management guidelines have some gaps regarding second-line treatment, combinations and there are no proposed algorithms. With the pragmatic trials, the investigators intend to fill the gap between the complicated randomized clinical trials and the observational studies. Using the treatments that have already been proved useful in SSc, in an open-label randomized way and based on some refined expert-made algorithms, will allow the investigators to establish the order in how to use them. Patients will be offered to participate with the collection of their clinical data and, if they give their consent, they will be randomized according to the algorithms. There will be an optional part of the study consisting in the collection of blood samples and skin samples for future research.
Systemic Sclerosis Clinical Trials
View 21 Systemic Sclerosis medical studies.
Monoclonal Antibodies
Brentuximab Vedotin for Systemic Sclerosis
This trial aims to test the safety and effectiveness of Brentuximab vedotin in patients with a certain type of skin disease called diffuse cutaneous systemic sclerosis who have not responded well to previous treatment
Behavioural Intervention
Online Fatigue Management for Scleroderma
This trial is testing whether an online fatigue management program can help reduce fatigue, pain, and increase confidence in managing fatigue and daily activities. It involves completing surveys before and after the intervention, and attending and participating in 1.5 hour weekly videoconference meetings for 6 weeks.
Skin involvement for Systemic Sclerosis
Systemic Sclerosis (SSc) is an autoimmune connective tissue disease characterized by autoantibodies, fibrosis and microvascular injury and endothelial cell activation that results in vascular damage. Vascular injury induces both innate and acquired immune responses resulting in fibroblast activation and organ fibrosis. SSc may target multiple organs, including: skin, lungs, heart, vascularization, kidneys, the gastrointestinal tract and musculoskeletal structures. Mortality among scleroderma patients is significant, with a 3.5 standardized mortality ratio (SMR) in studies of prevalent cases. This mortality may be increased in the early years of the disease, reaching a SMR of 4 in a multinational inception cohort. In general, treatment strategies target involved organs as early as possible to avoid damage. Many treatment options are available for each manifestation, but evidence with respect to the order of treatment is scarce. Financial costs, the lack of proper outcome measures, difficulty to recruit patients as a rare disease, all prevent the development of new big clinical trials, oppositely to other common diseases such as stroke or cancer. The heterogeneous features of SSc may make trials challenging. The current guidelines available are the British guidelines (2017) , and the updated European League Against Rheumatism (EULAR) guidelines, published in 2017. Management guidelines have some gaps regarding second-line treatment, combinations and there are no proposed algorithms. With the pragmatic trials, the investigators intend to fill the gap between the complicated randomized clinical trials and the observational studies. Using the treatments that have already been proved useful in SSc, in an open-label randomized way and based on some refined expert-made algorithms, will allow the investigators to establish the order in how to use them. Patients will be offered to participate with the collection of their clinical data and, if they give their consent, they will be randomized according to the algorithms. There will be an optional part of the study consisting in the collection of blood samples and skin samples for future research.
Morphea Clinical Trials With No Placebo
View 36 morphea medical studies that do not have a placebo group.
Monoclonal Antibodies
Brentuximab Vedotin for Systemic Sclerosis
This trial aims to test the safety and effectiveness of Brentuximab vedotin in patients with a certain type of skin disease called diffuse cutaneous systemic sclerosis who have not responded well to previous treatment
Behavioural Intervention
Online Fatigue Management for Scleroderma
This trial is testing whether an online fatigue management program can help reduce fatigue, pain, and increase confidence in managing fatigue and daily activities. It involves completing surveys before and after the intervention, and attending and participating in 1.5 hour weekly videoconference meetings for 6 weeks.
Endothelin Receptor Antagonist
Macitentan for Interstitial Lung Disease
Patients with interstitial lung disease (ILD) and scleroderma who develop pulmonary hypertension (PH) do not fit well into the current classification system and treatments for pulmonary hypertension. This study aims to better understand patients with ILD-PH and scleroderma and to determine if treatment with Macitentan is beneficial.
View More Morphea Trials
See another 15 medical studies focused on morphea.
Frequently Asked Questions
Introduction to morphea
What are the top hospitals conducting morphea research?
When it comes to clinical trials focused on morphea, a rare skin condition characterized by thickened and discolored patches of skin, several hospitals are leading the way. In London, the Rheumatology Clinic at St. Joseph's Health Care is actively conducting two trials dedicated to understanding and treating this condition. Although they have no recorded past trials for morphea, their commitment to current research demonstrates their dedication to finding solutions for patients.
Meanwhile, in Omaha, Nebraska, both the University of Nebraska Medical Center's Lauritzen Outpatient Center and Nebraska Medicine's Dermatology Westroads are contributing significantly as well. These institutions each have one active trial related to morphea and have also conducted one previous trial in the field since embarking on their respective journeys in 2023.
Additionally making strides in this area is Utah's University of Utah MidValley Dermatology where there is currently one ongoing clinical trial specifically targeting morphea alongside having accomplished another such study back when they initiated their first ever investigation into this particular field dated until 2020.
Lastly but not least Mayo Clinic situated amidst Arizona’s Scottsdale region continues being an integral part within fight against Morphea through its contemporary efforts with singleir ongoing clinical test while carrying out a precedent experiment nearly spanning over a year from2012 till present day
These leading hospitals serve as valuable centers for individuals affected by morphea who seek innovative treatments or hope to contribute to scientific advancements through participation in these essential trials. As we continue expanding our knowledge about this complex condition which affects so many lives globally; thus every small step taken towards understanding it better brings us closer creating new opportunities that offer support & renewed confidence those living with Morhpea
Which are the best cities for morphea clinical trials?
When it comes to morphea clinical trials, several cities are at the forefront of research. London, Ontario, Boston, Massachusetts, Houston, Texas, Omaha Nebraska and Scottsdale Arizona each have active trials focused on advancing our understanding and treatment options for this condition. These trials explore a variety of interventions such as Extracorporeal Photopheresis (ECP), Brentuximab Vedotin, Peripheral Blood Stem Cell Transplantation, Scleroderma treatments and more. By participating in these trials in these cities individuals with morphea can contribute to the development of new therapies that hold promise for improved outcomes.
Which are the top treatments for morphea being explored in clinical trials?
Clinical trials are shedding light on promising treatments for morphea, a condition characterized by hardened, discolored patches on the skin. Leading the charge is ixazomib, currently being explored in one active trial dedicated to morphea. This novel treatment option entered the scene in 2021 and shows great potential in addressing the symptoms of this rare skin disorder. Another contender making waves is sildenafil, which has caught researchers' attention with its inclusion in two all-time clinical trials for morphea since its first listing back in 2010. As these investigations progress, hope grows that new therapeutic breakthroughs will emerge to improve the lives of individuals affected by morphea worldwide.
What are the most recent clinical trials for morphea?
Exciting advancements are being made in the field of morphea, with several recent clinical trials offering hope for patients. One such trial focuses on anifrolumab, administered through subcutaneous weekly injections. In Phase 3, this treatment option became available on 7/13/2023 and holds promise for managing morphea symptoms effectively. Additionally, ongoing research is exploring the effectiveness of COVID-19 vaccines in addressing morphea, demonstrating potential benefits following Phases 2 and 3 that became available on 3/9/2022. Sildenafil has also shown promise in a Phase 2 trial conducted from 9/20/2021 onwards as a potential therapeutic option for those affected by morphea. These developments showcase the dedication to finding innovative solutions to improve quality of life for individuals battling this condition.
What morphea clinical trials were recently completed?
Recently, a clinical trial investigating the efficacy of Pirfenidone (PFD) in treating morphea reached completion. Led by Michael Roth, this study concluded in November 2017. While it is not within the timeframe of "recent" as per current information, this trial holds significance as an important contribution to our understanding and potential treatment options for morphea.